Company intelligence / Profile preview

AppoG

Waltham, Massachusetts, United Statesapps.apple.com ↗

Ownership: Private
Employees: ~93
Development stage: Other

Overview

Apogee Therapeutics is advancing a pipeline of differentiated monoclonal antibody therapeutics targeting well-established biological drivers in immunological and inflammatory diseases. Its lead candidate, APG777, is being developed for atopic dermatitis and has entered clinical trials. The company aims to file INDs for additional programs annually over the next several years. Clinical results are early-stage as of June 2025.

Therapeutic areas: DermatologyImmunologyPulmonology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Paragon Therapeutics (originating partner/spinout relationship)No major pharma partnerships publicly announced as of June 2025.

Beyond the preview

Go deeper on AppoG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AppoG.

Explore the full profile